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ABSTRACT
Introduction: Directly recorded patient experi-
ence of symptoms and health-related quality of
life (HRQoL) can complement lung function
and exacerbation rate data in chronic obstruc-
tive pulmonary disease (COPD) clinical studies.
The FULFIL study recorded daily symptoms and
activity limitation together with additional
patient-reported outcomes of dyspnea and
HRQoL, as part of the prespecified analyses.
FULFIL co-primary endpoint data have been
previously reported.
Methods: FULFIL was a phase III, 24-week,
randomized, double-blind, double-dummy,
multicenter study comparing once-daily single
inhaler triple therapy [fluticasone furoate/ume-
clidinium/vilanterol (FF/UMEC/VI)] 100 lg/
62.5 lg/25 lg with twice-daily inhaled corti-
costeroid/long-acting b2-agonist therapy
[budesonide/formoterol (BUD/FOR)] 400 lg/
12 lg in patients with symptomatic COPD at
risk of exacerbations. A subset participated for
52 weeks. Patient-reported assessments were:
Evaluating Respiratory Symptoms in COPDTM
(E-RS: COPD), St George’s Respiratory Ques-
tionnaire (SGRQ) for COPD, COPD Assessment
Test (CAT), baseline and transitional dyspnea
indices (TDI) and daily and global anchor
questions for activity limitation.
Results: FF/UMEC/VI showed greater reduc-
tions from baseline in 4-weekly mean E-RS:
COPD total and all subscale scores compared
with BUD/FOR; differences were statistically
significant (P\0.05) at each time period. FF/
UMEC/VI also demonstrated greater improve-
ments from baseline at weeks 4 and 24 in SGRQ
domain scores and TDI focal score compared
with BUD/FOR. At weeks 4 and 24, improve-
ments greater than the minimal clinically
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important difference from baseline were
observed in CAT score with FF/UMEC/VI, but
not BUD/FOR; differences were statistically sig-
nificant (P B 0.003).
Conclusion: These findings demonstrate sus-
tained daily symptom and HRQoL benefits of
FF/UMEC/VI versus BUD/FOR. The inclusion of
the CAT may provide data that are readily
generalizable to everyday clinical practice.








Incorporating the patient perspective into clin-
ical studies is an important aspect of drug
development [1, 2]. Poor health-related quality
of life (HRQoL) in chronic obstructive pul-
monary disease (COPD) has been linked to the
impact of symptoms such as dyspnea, as well as
to physical impairment, decreased mental
health, and increased hospital readmission
[3–6]. Furthermore, some reports suggest that
improving HRQoL reduces economic and social
burdens on both individuals and society [7, 8].
Patient-reported outcome (PRO) measures are
therefore important when assessing the overall
impact of COPD. The inclusion in clinical
development of reliable tools to assess symp-
toms and HRQoL can, therefore, provide infor-
mation that complements other efficacy
measures, giving a more comprehensive view of
the response to treatment and guiding clinical
practice [9].
Comparative patient-reported data for COPD
therapies are limited, [10, 12] with some initial
reports suggesting an improvement in HRQoL
with open triple therapy compared with dual
therapy in patients with symptomatic COPD
[10–12]. FULFIL (NCT02345161; GSK study
CTT116853) is the first study to compare once-
daily single inhaler triple therapywithfluticasone
furoate/umeclidinium/vilanterol (FF/UMEC/VI)
100 lg/62.5 lg/25 lg using the ELLIPTA inha-
ler with twice-daily dual therapy with budes-
onide/formoterol (BUD/FOR) 400 lg/12 lg
using the Turbuhaler in patients with symp-
tomatic COPD at risk of exacerbations [13].
Previously published findings showed signifi-
cant improvements in the co-primary end-
points of lung function and HRQoL as measured
by the COPD-specific St George’s Respiratory
Questionnaire (SGRQ), and in exacerbation
rates at week 24 with FF/UMEC/VI compared
with BUD/FOR [13]. The safety profile of FF/
UMEC/VI was consistent with the known safety
profiles of the individual dual- and monother-
apy components [13]. In addition, FULFIL was
also designed to prospectively assess symptoms
and physical activity, using daily and periodic
PRO assessment in patients receiving FF/UMEC/
VI or BUD/FOR. The COPD Assessment Test
(CAT) was also included as an additional mea-
sure of health status directly relevant to clinical
practice [13].
METHODS
FULFIL was a phase III, randomized, double-
blind, double-dummy, parallel-group, multi-
center study (Fig. S1 in the online data supple-
ment) [13]. Co-primary outcomes evaluated the
effects of fluticasone furoate/umeclidinium/vi-
lanterol (FF/UMEC/VI) on trough forced expi-
ratory volume in 1 s (FEV1) and St George’s
Respiratory Questionnaire (SGRQ) [14] total
score compared with budesonide/formoterol
(BUD/FOR) after 24 weeks of treatment. Sec-
ondary and other endpoints that were part of
the primary reporting from FULFIL included
respiratory symptoms severity (Evaluating Res-
piratory Symptoms in COPDTM [E-RS: COPD]
and subscales [15, 16], Transition Dyspnea
Index [TDI] focal score [17–19], and Global
Rating of Change in COPD Severity), rescue
medication use, and inhaler preference [13].
The CAT was included as an additional HRQoL
endpoint so as to provide information on
health status using data that can be incorpo-
rated easily into clinical practice, provide addi-
tional data on the relationship to SGRQ total
score, and relate to the Global Initiative for
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Chronic Obstructive Lung Disease assessment of
COPD severity [20–22].
Patients
FULFIL enrolled male and female patients with
COPD aged C 40 years with symptomatic COPD
at risk of exacerbation:
• CAT score C 10,
• And either
• forced expiratory volume in 1 s \50%
(no exacerbation history requirement)
• or forced expiratory volume in 1 s
50–80% with a history of exacerbations
in the previous year (C 2 moderate or C 1
exacerbation requiring hospitalization).
Patients were randomized to receive
24 weeks of once-daily FF/UMEC/VI (100 lg/
62.5 lg/25 lg) using a single ELLIPTA inhaler
or twice-daily BUD/FOR (400 lg/12 lg) using
the Turbuhaler (intent-to-treat [ITT] popula-
tion) [13]. A subset of patients remained on
blinded study treatment for up to 52 weeks
[extension (EXT) population].
Patients were required to be receiving daily
maintenance therapy for chronic obstructive
pulmonary disease (COPD) for C 3 months,
with medications at screening that continued
unchanged during the 2-week run-in period.
Patients were excluded if they had a current
diagnosis of asthma, COPD caused by a1-antit-
rypsin deficiency, other respiratory disorders,
lung resection within 12 months of screening,
or any other clinically significant diseases.
Patients who had pneumonia or a severe COPD
exacerbation that had not resolved within
14 days of screening, a respiratory tract infec-
tion that had not resolved within 7 days of
screening, or an abnormal chest X-ray were also
excluded.
The study protocol was reviewed and
approved by the relevant investigational center
ethics committee or institutional review board,
in accordance with the International Council
on Harmonisation. The study was conducted in
accordance with the Declaration of Helsinki and
all participants provided written informed
consent.
Patient-Reported Outcome Tools
Patients used an electronic diary each evening
to complete the E-RS: COPD [derived from
EXAcerbations of Chronic pulmonary disease
Tool (EXACT)], record rescue medication use,
and limitation in daily activities questions. The
COPD-specific SGRQ and CAT were used to
assess HRQoL at study visits; this article reports
SGRQ domain scores of symptoms, activity, and
impacts (total score results have been previously
reported elsewhere) [13]. The TDI focal score
(self-administered computerized version) was
used to assess dyspnea. Global Ratings of COPD
Severity and activity limitation were assessed at
randomization, and Global Rating of Change
from Baseline in Severity and activity limitation
at all visits post-randomization. The double-
dummy study design enabled patients to
express preference between the inhalers;
responses were obtained using the COPD Inha-
ler Preference Questionnaire at week 24 (or at
treatment discontinuation, if applicable) [23].
Patients were asked which inhaler they pre-
ferred, based on number of steps, time taken,
and ease of use: the response options were
ELLIPTA, Turbuhaler or no preference. The form
and timing of these assessments are summa-
rized in Table 1.
Statistical Analyses
Prespecified analyses were performed in the ITT
population for data up to week 24, and in the
EXT population for data up to week 52. Mean
scores for the E-RS: COPD and the three sub-
scales over 4-week intervals, change from base-
line in CAT scores, TDI focal scores, and mean
number of occasions of rescue medication use
per day over the 4-week intervals were all ana-
lyzed using a mixed model repeat measures
analysis including treatment group, smoking
status at screening, geographical region, visit,
baseline value, and baseline-by-visit and treat-
ment group-by-visit interactions. The propor-
tions of responders on SGRQ, CAT, E-RS: COPD
and TDI (response defined as a change from
baseline equal to or greater than MCID
[Table 1]) and non-responders were analyzed
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Table 1 Assessment tools used in patient-reported data collection
Assessment tools Time points completeda Summary
E-RS: COPD [15, 16] Daily 11 respiratory symptom items contained in
the 14-item EXACT
Total score represents overall respiratory
symptom severity and the three subscales
assess breathlessness, cough and sputum,
and chest-related symptoms
MCID: C 2-unit improvement (decrease)
from baseline for total score
CAT [20, 21] Baseline, day 1, weeks 4 and 24,
week 52 (EXT)
Eight items, each with a 6-point response
scale, ranging from 0 (no impact) to 5
(high impact) with a scoring range of
0–40
MCID C 2-unit improvement (decrease in
score) from baseline
Rescue medication use Daily Number of occasions of rescue medication
use per day
TDI focal score [17–19] Weeks 4 and 24, week 52
(EXT)
Change in dyspnea severity on a 7-point
scale ranging from major deterioration to
major improvement
MCID: C 1-unit improvement (increase)
SGRQ-C [14] Day 1, week 4 and 24, week 52
(EXT)
40 items weighted by symptoms, activity,
and impacts with a scoring range of
0–100
Domain scores are calculable for symptoms,
activity, and impact
MCID C 4-unit improvement (decrease in
score) from baseline
Global rating of COPD severity Baseline, week 24, and 52
(EXT)
4-point scale (mild, moderate, severe, very
severe)
Change rated on a 7-point Likert scale
(much better, better, slightly better, no
change, slightly worse, worse, much worse)
Rating of change in COPD severity All study visits following
baseline
Daily activity question Baseline, week 24, and 52
(EXT)
3-point scale: 0 = I did fewer activities than
usual; 1 = There was no effect on my
activities; 2 = I did more activities than
usual
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using a generalized linear mixed model with a
logit link function. Number need to treat to
benefit was calculated (post hoc) for E-RS:
COPD, TDI, CAT and SGRQ total scores.
The proportion of days that a patient repor-
ted a score of 0 (less activity than usual), 1 (the
same activity as usual), or 2 (more activity than
usual) on the daily activity question was deter-
mined for the weeks 1–24 period for the ITT
population and weeks 1–52 for the EXT popu-
lation. The proportion of days with a score of 2
(able to perform more activities than usual) on
the daily activity question was analyzed using
an analysis of covariance model and included
the following covariates: treatment group,
screening smoking status, geographical region,
and baseline value. Patient Global Ratings of
Change in Activity Limitation and Change in
COPD Severity were analyzed separately at each
visit, using logistic regression including treat-
ment, screening smoking status, and geo-
graphical region as covariates. The proportion
of patients who reported a preference for either
inhaler or no preference was presented. For
patients who expressed a preference for either
ELLIPTA or Turbuhaler, P values were calcu-
lated (post hoc) to test whether the proportion
of patients who preferred ELLIPTA differed
significantly from 50%.
RESULTS
The ITT population comprised 1810 patients
(FF/UMEC/VI, n = 911; BUD/FOR, n = 899). The
EXT population included the first 430 of these
patients who consented to receive treatment for
52 weeks (FF/UMEC/VI, n = 210; BUD/FOR,
n = 220) (Fig. 1). The full population character-
istics are shown in Table S1 in the online data
supplement, as reported in the primary publi-
cation [13]. Baseline demographics and PRO
scores were similar between treatment arms in
both the ITT and EXT populations, and between
the ITT and EXT populations (Table 2) [13].
COPD maintenance medication taken at
screening was comparable between treatment
arms and the ITT and EXT populations
(Table S2).
Symptom Assessments
Over 24 weeks (ITT), FF/UMEC/VI produced
greater reductions from baseline in mean E-RS:
COPD total score and all subscale scores com-
pared with BUD/FOR; treatment differences
were statistically significant for each 4-week
interval and in the FF/UMEC/VI group exceeded
the total score response threshold by week 8.
Breathlessness and cough and sputum subscales
Table 1 continued
Assessment tools Time points completeda Summary
Global rating of activity limitation Baseline, week 24, and 52
(EXT)
Activity limitation rated on a 4-point scale
(not limited, slightly limited, limited, very
limited)
Change rated on a 7-point Likert scale
(much better, better, slightly better, no
change, slightly worse, worse, much worse)
Rating of change in activity limitation All study visits following
baseline
CIPQ Week 24 (or study treatment
discontinuation visit)
Three questions regarding number of steps,
time taken, and ease of use
CAT COPD Assessment Test, CIPQ COPD Inhaler Preference Questionnaire, COPD chronic obstructive pulmonary
disease, E-RS: COPD Evaluating Respiratory Symptoms in COPD, EXACT EXAcerbations of Chronic pulmonary disease
Tool, EXT extension, MCID minimal clinically important difference, SGRQ-C St George’s Respiratory Questionnaire for
COPD, TDI Transition Dyspnea Index
a All time points speciﬁed are for the ITT population, unless otherwise speciﬁed
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in this group exceeded the threshold by week 12
(Fig. 2). The between-treatment odds ratios
(ORs) of response versus non-response over
24 weeks (ITT) were statistically significant in
favor of FF/UMEC/VI (OR range over 24 weeks,
1.59–1.76; all P\0.001). At weeks 21–24 (ITT)
for FF/UMEC/VI versus BUD/FOR, 53 and 42%
of patients responded, respectively, and the
number needed to treat to benefit (NNTB) was 9
(95% CI 7–17). Similar findings were observed
for OR response versus not response at each
4-week interval over 52 weeks in the EXT
Fig. 1 CONSORT ﬂow chart for the FULFIL study. BUD/FOR budesonide/formoterol, FF/UMEC/VI ﬂuticasone
furoate/umeclidinium/vilanterol, ITT intent-to-treat
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population [Table S23 in the online data sup-
plement; proportion of responders: 42 and 32%
for FF/UMEC/VI and BUD/FOR, respectively;
NNTB of 10 (95% CI 5–77)].
FF/UMEC/VI also demonstrated statistically
significant improvements in dyspnea, measured
by mean TDI focal score, compared with BUD/
FOR at weeks 4 and 24 in the ITT population
(Table 3). Between-treatment ORs of response
versus non-response at weeks 4 and 24 (ITT)
were statistically significant in favor of FF/
UMEC/VI [week 4 OR (95% CI): 1.52
Table 2 Patient characteristics at baseline (ITT and EXT populations)













Mean age, years (SD) 64.2 (8.56) 63.7 (8.71) 63.7 (7.76) 63.3 (8.43)
Female, n (%) 233 (26) 236 (26) 53 (25) 58 (26)
FEV1, mean (SD) 1.28 (0.46) 1.27 (0.47) 1.33 (0.50) 1.28 (0.48)
% Predicted FEV1, mean (SD) 42.5 (13.01) 41.8 (13.48) 44.1 (13.36) 41.7 (14.07)
E-RS: COPD total score, mean (SD) 13.20 (5.83) 12.97 (5.93) 13.54 (5.44) 13.00 (5.58)
SGRQ domain scores, mean (SD)
Symptoms 67.4 (18.35) 67.2 (18.71) 70.0 (18.65) 68.7 (18.79)
Activity 64.2 (17.64) 63.1 (18.28) 65.1 (17.73) 62.6 (16.57)
Impacts 39.9 (19.48) 38.6 (19.98) 40.8 (19.32) 38.4 (18.36)
CAT score, mean (SD) 17.6 (6.43) 17.8 (6.24) 18.1 (6.29) 17.7 (5.93)
Global rating of COPD severity, n (%)
Mild 89 (10) 92 (10) 12 (6) 21 (10)
Moderate 594 (66) 604 (68) 143 (68) 152 (70)
Severe 207 (23) 181 (20) 51 (24) 42 (19)
Very severe 12 (1) 7 (\1) 3 (1) 2 (\1)
Global rating of activity limitation, n (%)
Not limited 47 (5) 43 (5) 7 (3) 5 (2)
Slightly limited 366 (41) 382 (43) 77 (37) 94 (43)
Limited 424 (47) 404 (46) 107 (51) 102 (47)
Very limited 63 (7) 55 (6) 18 (9) 16 (7)
Number of occasions of rescue medication
use per day, mean (SD)
1.8 (2.07) 1.8 (2.04) 1.6 (1.95) 1.5 (1.87)
BUD/FOR budesonide/formoterol, CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, E-RS:
COPD Evaluating Respiratory Symptoms in COPD, EXT extension, FEV1 forced expiratory volume in 1 s, FF/UMEC/VI
ﬂuticasone furoate/umeclidinium/vilanterol, ITT intent-to-treat, SD standard deviation, SGRQ St George’s Respiratory
Questionnaire
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(1.25–1.86), P[0.001; week 24 OR (95% CI):
1.61 (1.33–1.95), P\0.001]. At week 24 (ITT),
61 and 51% of patients responded on FF/UMEC/
VI and BUD/FOR, respectively, and the NNTB
was 10 (95% CI 7–18). In the EXT population at
week 52, there was no evidence of benefit, the
OR was 1.35 (P = 0.1.32) and 53 and 46%
responded, respectively. The mean TDI focal
score showed numeric improvement with FF/
UMEC/VI compared with BUD/FOR at weeks 4,
24, and 52 (EXT) but only achieved statistical
significance at week 4 (P = 0.01). However, the
ratio between treatments of odds of response
versus non-response for the E-RS: COPD
Breathlessness Score for each 4-weekly period in
the EXT population ranged from 1.60 to 2.32
(all P\0.05). The observed improvements in
symptom scores were independent of baseline
COPD medication.
A statistically significant reduction in mean
number of occasions of rescue medication use
per day was demonstrated with FF/UMEC/VI
versus BUD/FOR over weeks 1–24 (ITT) and
weeks 1–52 (EXT) (Table 4). Similar findings
were observed at each 4-week time period
(Table 4).
HRQoL Assessments
In the ITT population at weeks 4 and 24, clini-
cally meaningful improvements from baseline
in CAT score (reduction C 2) were observed with
Fig. 2 Mean change from baseline in 4-weekly E-RS:
COPD scores (ITT): total score (a); breathlessness (b);
cough and sputum (c); chest symptoms (d). Dark dotted
lines represent baseline and light dotted lines represent
response threshold. BUD/FOR budesonide/formoterol, CI
conﬁdence interval, E-RS: COPD Evaluating Respiratory
Symptoms in COPD, FF/UMEC/VI ﬂuticasone furoate/
umeclidinium/vilanterol, ITT intent-to-treat, LS least
squares
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FF/UMEC/VI (mean change from baseline: week
4, - 1.7; week 24, - 2.7), but not with BUD/FOR
(mean change from baseline: week 4, - 1.4;
week 24, - 1.7). The treatment differences of
- 0.7 and - 0.9 units, respectively, were statis-
tically significant (Fig. 3). In the smaller EXT
population, improvements from baseline were
also observed at weeks 4, 24, and 52 with both
treatments, numerically in favor of FF/UMEC/
VI, but the treatment difference was only sta-
tistically significant at week 24 (P = 0.035). The
OR of response versus non-response at week 24
Table 3 Analysis of TDI focal scores and proportion of TDI responders in the ITT and EXT populations













Baseline dyspnea index, mean (SD) 5.7 (1.77) 5.5 (1.83) 5.9 (1.58) 5.5 (1.70)
Week 4




















0.26 (- 0.32 to 0.84)
0.373








LS mean (95% CI) 1.74 (1.30–2.17) 1.39 (0.95–1.84)
Difference (95% CI)
P value
0.34 (- 0.28 to 0.97)
0.279





TDI focal score range is – 9 to 9 (lower scores indicate more deterioration in severity of dyspnea). Response deﬁned as a
score of C 1
BUD/FOR budesonide/formoterol, CI conﬁdence interval, EXT extension, FF/UMEC/VI ﬂuticasone furoate/umecli-
dinium/vilanterol, ITT intent-to-treat, LS least squares, OR ratio of odds of response versus non-response, SD standard
deviation, TDI Transition Dyspnea Index
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(ITT) was statistically significant in favor of FF/
UMEC/VI versus BUD/FOR (OR 1.44, P\0.001).
At week 24 (ITT), 53 and 45% of patients
receiving FF/UMEC/VI or BUD/FOR responded,
respectively, and the NNTB was 11 (95% CI
8–29). At week 52 (EXT), the OR was 1.50
(P = 0.048) and the proportions of responders
were 44 versus 35%, respectively, [NNTB, 11
(95% CI 5–459)]. Similar findings were observed
in SGRQ analyses. At week 24 (ITT), the OR of
response versus non-response was statistically
significant in favor of FF/UMEC/VI versus BUD/
FOR (OR 1.41, P\0.001). At week 24 (ITT), 50
and 41% of patients receiving FF/UMEC/VI or
BUD/FOR responded, respectively, and the
NNTB was 12 (95% CI 8–27). At week 52 (EXT),
the OR was 1.50 (P = 0.046) and the proportions
of responders were 44 versus 33%, respectively
(NNTB, 10 [95% CI 5–97]).
Improvements from baseline in SGRQ
domain scores were observed in both treatment
groups in the ITT population in line with
changes in the total score [13], with signifi-
cantly greater improvements observed with FF/
UMEC/VI across all domain scores compared
with BUD/FOR at weeks 4 and 24 (Fig. 4).
Improvements from baseline in SGRQ domain
scores were also observed in both treatment
groups at weeks 4, 24, and 52 in the EXT pop-
ulation numerically in favor of FF/UMEC/VI at
all time points, except for Symptoms and
Impacts domains at week 4 (Table S3 in the
online data supplement).
The FF/UMEC/VI group had significantly
greater odds of being in a better versus a worse
response category for patient-rated Global Rat-
ing of Change in COPD Severity from baseline
at week 24 (ITT) compared with BUD/FOR
[ordered OR 1.63; 95% confidence interval (CI)
1.37–1.95] and at week 52 (EXT) population
(ordered OR 2.08; 95% CI 1.42–3.06). All
HRQoL findings were observed independent of
baseline COPD medication. The relationship
between SGRQ and CAT scores was explored
Table 4 Treatment difference in rescue medication use







Weeks 1–24 (ITT) - 0.2 \0.001
Weeks 1–52 (EXT) - 0.2 0.019
Weeks 21–24 (ITT) - 0.3 \0.001
Weeks 49–52 (EXT) - 0.5 0.003
BUD/FOR budesonide/formoterol, EXT extension, FF/
UMEC/VI ﬂuticasone furoate/umeclidinium/vilanterol,
ITT intent-to-treat
Fig. 3 Mean change in baseline in CAT score in the ITT
population. BUD/FOR budesonide/formoterol, CAT
COPD Assessment Test, CI conﬁdence interval, FF/
UMEC/VI ﬂuticasone furoate/umeclidinium/vilanterol,
ITT intent-to-treat, LS least squares, SE standard error
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post hoc using individual patient data and
demonstrated a positive correlation between
the changes from baseline in SGRQ total score
and in CAT score at week 24 in the ITT popu-
lation (Fig. 5).
Activity Limitation and Inhaler Preference
At baseline, most patients reported some level
of COPD-related limitation in activity, with
similar proportions in each arm reporting
slightly limited or limited activity and only a
few patients reporting the extremes of no limi-
tation or very limited activity.
At weeks 24 (ITT population) and 52 (EXT
population), compared with baseline, more
patients treated with FF/UMEC/VI reported
improved activity limitation (‘not limited’ and
‘slightly limited’ categories) on the Global Rat-
ing of Activity Limitation (13 and 15% increa-
ses) compared with BUD/FOR (5% increases at
each week).
Patients receiving FF/UMEC/VI had statisti-
cally significantly greater odds of being in a
better response category versus a worse category
for Change in Global Activity Limitation than
those treated with BUD/FOR at week 24 (ITT)
(ordered OR 1.58; 95% CI 1.33–1.89) and week
52 (EXT) (ordered OR 2.15; 95% CI 1.46–3.16).
Responses to the daily activity question were
not easily interpreted as only 5% (approxi-
mately) of patients in each group reported an
improvement in the number of days they were
able to perform more activities than usual. At
baseline in both the ITT and EXT populations,
the majority of patients in each treatment arm
(55–58%) reported a score of 1 (no effect on
activities) and approximately 40% reported a
score of 0 (fewer activities than normal).
At the final study visit (week 24, ITT popu-
lation), of those patients who expressed a pref-
erence, more preferred the ELLIPTA inhaler to
the Turbuhaler (Table 5).
DISCUSSION
The planned inclusion of reliable and respon-
sive PRO tools and the prespecified analyses of
Fig. 4 Mean change from baseline in SGRQ domain
scores in the ITT population. Treatment differences (95%
CIs) shown. *P\0.05; **P\0.01; ***P\0.001. BUD/
FOR budesonide/formoterol, CI conﬁdence interval, FF/
UMEC/VI ﬂuticasone furoate/umeclidinium/vilanterol,
ITT intent-to-treat, LS least squares, SGRQ St George’s
Respiratory Questionnaire
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these data in the FULFIL study allows the
patient perception of real-life disease impact
and severity to be more fully described. In the
study, rapid and sustained reductions in daily
symptoms assessed by the E-RS: COPD and
subscales alongside improvement in HRQoL
were demonstrated for both treatment groups.
Although it was expected that a reduction in
symptoms, particularly dyspnea, would also be
reflected in improved activity levels, this was
not clearly demonstrated in the daily activity
question as very few patients reported the abil-
ity to perform more than usual activities.
However, when responding to the Global
Rating of Change in Activity question, patients
in both groups were more likely to report
improved activity than reduced activity at week
24. Measurement and monitoring of activity in
COPD patients is an emerging area for study;
patient motivation and habit are likely to affect
the magnitude of reported change [24].
In clinical studies, PRO measures provide
insights into patient perception of symptom
severity and changes alongside the use of
physiological measures and can demonstrate
the overall impact of treatment. The use of daily
diary measures of symptoms such as E-RS:
COPD captures time of data entry and
Fig. 5 Change from baseline in CAT score versus change
from baseline in SGRQ total score at week 24 in the ITT
population. Line represents line of best ﬁt. Fitted regres-
sion line using the SAS procedure SGPLOT with a REG
statement. BUD/FOR budesonide/formoterol, CAT COPD
Assessment Test, FF/UMEC/VI ﬂuticasone furoate/umecli-
dinium/vilanterol, ITT intent-to-treat, SGRQ St George’s
Respiratory Questionnaire
Table 5 Inhaler preferences at week 24 (n = 1810; ITT population)
Factor Completed question Expressed a preference Preference, n (%) P value
ELLIPTA Turbuhaler
Number of steps 1736 1131 869 (77) 262 (23) \0.01
Time taken 1736 1114 853 (77) 261 (23) \0.01
Ease of use 1736 1173 906 (77) 267 (23) \0.01




minimizes patient recall issues, which can be
seen with periodic assessment. It is also possible
to determine the timing of symptom improve-
ment by examining symptom patterns and sta-
bility in individual patients. Early changes to
HRQoL measures (SGRQ and CAT) at week 4 are
mostly driven by the reduction in symptoms,
and this is reflected in the E-RS: COPD and TDI
focal scores, which also show early improve-
ment. The particular improvements in dyspnea
measures for FF/UMEC/VI over BUD/FOR are
expected from the addition of a second bron-
chodilator. The SGRQ symptoms domain and
the E-RS: COPD subscales of cough and sputum
and chest symptoms improve more slowly, as
do the SGRQ domains of activity and impacts,
which are less immediately or directly affected
by bronchodilation.
In FULFIL, both treatments produced
improvements in HRQoL at weeks 4 and 24,
seen in improvements in both CAT scores
reported here and SGRQ total scores (previously
reported: FF/UMEC/VI, - 4.2 and - 6.6; BUD/
FOR, - 2.5 and - 4.3, respectively) [13]. Mean
changes from baseline in the FF/UMEC/VI
group were statistically superior to those in the
BUD/FOR group for both CAT and SGRQ total
scores. However, whilst the SGRQ total score is
an accepted measure of HRQoL in clinical
research, the COPD-specific SGRQ is a difficult
tool to use and interpret in daily clinical prac-
tice. In development, CAT demonstrated similar
measurement properties to the SGRQ [25, 26],
and in FULFIL we examined this relationship in
a post hoc analysis of the ITT population. CAT is
a measure that can be easily incorporated into
routine clinical practice with limited additional
burden on patients and healthcare profession-
als. This makes the results of FULFIL more
immediately useful to clinicians. Furthermore,
because CAT is easy to administer and interpret,
it is more likely to be performed in routine care.
When comparing changes in PRO scores
between treatment groups, it is important to
consider whether the change from baseline
within the groups is clinically meaningful, in
order to provide context for the mean differ-
ences between groups. In a study comparing
two active treatments, such as FULFIL, both
groups in the study might be expected to
improve from baseline; therefore, a responder
analysis such as that reported here provides the
most meaningful comparison, since achieving a
between-groups difference greater than the
minimal clinically important difference is not
to be expected.
The prespecified analyses of PROs from
FULFIL presented here build on the primary
findings [13] and further demonstrate that FF/
UMEC/VI improved patient perceptions of both
symptom severity and health status, compared
with BUD/FOR. In addition, these results show
that a larger proportion of patients preferred
using the ELLIPTA inhaler compared with the
Turbuhaler. The findings were also observed in
the EXT population over 52 weeks, demon-
strating that these effects were maintained over
the long term.
CONCLUSIONS
These results show that therapy with once-daily
triple therapy with FF/UMEC/VI improves
patient symptoms and HRQoL compared with
twice-daily BUD/FOR. The inclusion of patient
perspectives provides the clinician with addi-
tional information to assist choice and moni-
toring of therapies. The findings presented here
further illustrate the benefits of once-daily triple
therapy in patients with symptomatic COPD
who are at risk of exacerbation.
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